Expanding access to biologic medicines through biosimilars
Biopharma is Fresenius’ global biopharmaceutical business focused on the development, manufacturing and supply of biosimilars – biologic medicines that are highly similar to approved reference biologics in quality, safety and efficacy – to help expand access to advanced treatments for patients worldwide.
As demand for biologic medicines grows, healthcare systems are facing increasing pressure to meet the needs of people living with chronic and complex diseases.
Combining scientific expertise, integrated development and manufacturing capabilities, and global supply reach, our Biopharma teams help expand access to biologic medicines through biosimilars, supporting the long-term sustainability of healthcare systems worldwide.
Our ambition is to be a leading global biosimilars company, helping expand access to biologic medicines through a growing portfolio, integrated capabilities and global reach.
8x
increase in patient impact potential
The next decade is expected to expand access to biologic medicines on a scale not previously seen.1
100+ biologic medicines losing exclusivity by 2030
An unprecedented wave of biologic patent expiries is creating new opportunities for biosimilar development and patient access.1
>$100bn projected healthcare savings in EU and US by 2030
Biosimilars are expected to generate substantial savings that can be reinvested to support patient care, innovation and healthcare system sustainability.2
Demand for biologic medicines is rising as more people live with chronic and complex diseases. At the same time, an unprecedented wave of biologic medicines losing exclusivity is creating new opportunities to expand access for millions more patients. In Biopharma, we are helping expand access to biologic medicines through four priorities: innovation focused on patient needs, ensuring quality and resilient supply, supporting future-ready healthcare systems, and empowering people and partnerships.
We focus on biosimilars in areas where expanded access to biologic medicines can make a meaningful difference for patients and healthcare systems.
Our integrated value chain supports quality, supply resilience and the ability to scale globally.
Rigorous scientific evidence and manufacturing controls help safeguard product quality from development through to release.
Global infrastructure spanning more than 100 countries helps ensure reliable access to biosimilars worldwide.
We work with stakeholders across healthcare to support sustainable access, science-led policy environments and the long-term resilience of healthcare systems.
Targeting over 60% of biologics expected to lose exclusivity in the coming years.
Projected to support more than 1 billion patient treatment days by 2030.
Working to contribute more than €35 billion in cumulative healthcare savings across the EU and US alone by 2030.
Expanding access takes collaboration. We work across healthcare - with partners, healthcare professionals (HCPs), patient communities, policymakers and our own teams - to help biosimilars reach more people, responsibly.
A biosimilar is a biologic medicine that is highly similar to an already approved biologic medicine, known as the reference medicine. Biosimilars must meet rigorous regulatory standards and demonstrate no clinically meaningful differences in quality, safety and efficacy compared with the reference medicine.
Our biosimilar portfolio and pipeline span multiple disease areas, including autoimmune diseases and cancer. We support access not only through our medicines, but also through education, patient support programs and partnerships that help patients and healthcare professionals navigate treatment journeys where available locally.
References:
1. Assessing the Biosimilar Void. IQVIA Report (2023). Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void [Last accessed: July 2026]
2. 'Meet the Management' © Fresenius SE & Co. KGaA Investor Relations (2025). Available at: Biopharma 'Meet the Management' [Last accessed: July 2026]
